Harnessing the differentiated capabilities of mRNA for rare diseases

Having blazed a trail in the application of mRNA in the prophylactic vaccine setting, Moderna is now engaged in expanding the reach of this technology into the therapeutic sphere. David McCall, Senior Editor, Nucleic Acid Insights, spoke with Paolo Martini, Chief Scientific Officer of the International Therapeutics Research Centers at Moderna, about the potential to transform the lives of patients with rare diseases.

Please enter your email to access content Read now